Gene · 6613
SUMO2: small ubiquitin like modifier 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SUMO2: small ubiquitin like modifier 2. Genes, record 6613. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6613
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P61956 | Small ubiquitin-related modifier 2 | 95 | 25 | Ensembl, GeneID, HGNC |
Source UniProt
Patents51
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026108757 A | 2026-06-30 | 33 | P61956 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 13376 | P61956 | Espacenet |
| US 12351611 B2 | 2025-07-08 | 33 | P61956 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 13376 | P61956 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 15969 | P61956 | Espacenet |
| US 12091437 B2 | 2024-09-17 | 33 | P61956 | Espacenet |
| KR 1020240102916 A | 2024-07-03 | 242 | P61956 | Espacenet |
| US 11976100 B2 | 2024-05-07 | 39 | P61956 | Espacenet |
| US 11891420 B2 | 2024-02-06 | 33 | P61956 | Espacenet |
| JP 2023523625 A | 2023-06-06 | 39 | P61956 | Espacenet |
1 to 10 of 51
See all 51 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,341
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SUMO2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 11 | 2025 |
| T32CA009110 | Training in Areas Fundamental to Cancer Research | 11 | 2025 |
| P30GM124165 | NE-CAT: A Resource for Advanced Macromolecular Crystallography | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 4 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 4 | 2025 |
| R01HD036071 | Genotype-Phenotype Relationships in Fragile X Families | 4 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 3 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
1 to 10 of 1,341Source NIH's project files
See all 1,341 nih grantsPapers2,290
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lumbrokinase ameliorates chronic social defeat stress-induced behavioral impairments through modulation of miR-340-5p and SUMO2 signaling. | Neuropharmacology | 2026 | 42716376 | PubTator, text mining | PubMed |
| PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization. | J Exp Med | 2026 | 42663568 | PubTator, text mining | PubMed |
| Ubiquitin-like proteins NEDD8 and SUMO2 control epithelial homeostasis, regeneration, and inflammation. | Science | 2026 | 42348677 | PubTator, text mining | PubMed |
| Direct Photoredox Synthesis of N-Linked Glycoproteins. | J Am Chem Soc | 2026 | 42329120 | PubTator, text mining | PubMed |
| TRIM28-mediated SUMOylation of SREBF1 drives PD‑L1 N‑glycosylation and immune evasion in bladder cancer. | Cell Death Dis | 2026 | 42151123 | PubTator, text mining | PubMed |
| Exon-skipping antisense oligonucleotides targeting SUMO1 and SUMO2 demonstrate chemosensitizing effects in NSCLC cells in tissue culture. | Res Sq | 2026 | 42147169 | PubTator, text mining | PubMed |
| Corrigendum to: "SUMO2-mediated SUMOylation of SH3GLB1 promotes ionizing radiation-induced hypertrophic cardiomyopathy through mitophagy activation'' [Europ. J. Pharmacol. 5 (2022) 174980 59897]. | Eur J Pharmacol | 2026 | 42115010 | PubTator, text mining | PubMed |
| UBA2-High Osteosarcoma Suppresses Immune Infiltration by Autophagy-Mediated MHC-I Degradation. | Cancer Immunol Res | 2026 | 42085301 | PubTator, text mining | PubMed |
| RETRACTION: Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion. | FEBS Open Bio | 2026 | 41983998 | PubTator, text mining | PubMed |
| Denaturing SUMO Immunoprecipitation From Mitotic Cells. | Bio Protoc | 2026 | 41971162 | PubTator, text mining | PubMed |
1 to 10 of 2,290
See all 2,290 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6613
GET https://conductscience.org/api/genes/v1/6613/patents?page=2